PT - JOURNAL ARTICLE AU - John Cannon AU - Colm McCabe AU - Joanna Pepke-Zaba AU - Karen Sheares TI - Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS) DP - 2012 Sep 01 TA - European Respiratory Journal PG - P948 VI - 40 IP - Suppl 56 4099 - http://erj.ersjournals.com/content/40/Suppl_56/P948.short 4100 - http://erj.ersjournals.com/content/40/Suppl_56/P948.full SO - Eur Respir J2012 Sep 01; 40 AB - Pulmonary hypertension is a recognised complication of sarcoidosis and may arise from several aetiological pathways. We report our experience of patients with PHAS-GroupV on targeted treatment.Retrospective study of patient outcomes with PHAS. All patients underwent right heart catheterisation satisfying criteria for diagnosis of PAH. We reviewed 16 patients, 10 of whom died in mean f/u 32m. Patients dichotomised into 2 groups (responders and non-responders) based on improvement in log ntproBNP and 6MWD within 6 months of therapy initiation.View this table:Treatment response was associated with a reduced risk of death. Cohort phenotypes suggest that treatment response may not be predicted from sarcoid stage, functional class, FVC or presence of extrapulmonary features. However elevation in PVR may possibly be associated with a favourable response. An RCT is indicated to evaluate a larger cohort.